DECIPHERA PHARMACEUTICALS IN's ticker is DCPH and the CUSIP is 24344T101. A total of 156 filers reported holding DECIPHERA PHARMACEUTICALS IN in Q4 2019. The put-call ratio across all filers is 0.31 and the average weighting 0.5%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2020 | $19,534,000 | -4.8% | 342,274 | -14.4% | 0.05% | -20.0% |
| Q3 2020 | $20,520,000 | -10.7% | 399,999 | +3.9% | 0.06% | -18.8% |
| Q2 2020 | $22,981,000 | +41.7% | 384,805 | -2.3% | 0.08% | +11.1% |
| Q1 2020 | $16,222,000 | -55.9% | 394,020 | -33.3% | 0.07% | -41.5% |
| Q4 2019 | $36,786,000 | +226.1% | 591,037 | +77.9% | 0.12% | +223.7% |
| Q3 2019 | $11,279,000 | +41.1% | 332,320 | -6.3% | 0.04% | +46.2% |
| Q2 2019 | $7,994,000 | +11.8% | 354,503 | +15.0% | 0.03% | +8.3% |
| Q1 2019 | $7,151,000 | +44.0% | 308,132 | +30.2% | 0.02% | +33.3% |
| Q4 2018 | $4,966,000 | -64.6% | 236,607 | -34.6% | 0.02% | -53.8% |
| Q3 2018 | $14,018,000 | -0.7% | 362,024 | +1.0% | 0.04% | -4.9% |
| Q2 2018 | $14,110,000 | +101.0% | 358,585 | +2.4% | 0.04% | +95.2% |
| Q1 2018 | $7,020,000 | +14.6% | 350,331 | +29.7% | 0.02% | +23.5% |
| Q4 2017 | $6,124,000 | +79.2% | 270,124 | +50.1% | 0.02% | +70.0% |
| Q3 2017 | $3,418,000 | – | 180,000 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| New Leaf Venture Partners, L.L.C. | 2,086,723 | $85,910,000 | 25.70% |
| SV Health Investors, LLC | 449,951 | $18,525,000 | 15.54% |
| Redmile Group, LLC | 5,116,263 | $210,637,000 | 5.90% |
| Eversept Partners, LP | 414,081 | $17,047,715 | 4.24% |
| Sunesis Advisors, LLC | 96,299 | $3,965,000 | 3.99% |
| Avoro Capital Advisors LLC | 2,000,000 | $82,340,000 | 2.78% |
| Opaleye Management Inc. | 222,000 | $9,140,000 | 2.42% |
| SECTORAL ASSET MANAGEMENT INC | 204,059 | $8,401,000 | 1.61% |
| Artal Group S.A. | 800,000 | $32,936,000 | 1.39% |
| Atika Capital Management LLC | 141,000 | $5,805,000 | 1.11% |